Dr. Hugh McTavish, Company Founder, President, and CEO of IGF Oncology, a biotech company developing targeted anti-cancer drugs, talks about their lead drug IGF-MTX, that targets the deadly blood cancer MDS (Myelodysplastic syndromes), and is currently in clinical trials at the Mayo Clinic.
Company Founder, President and CEO, Dr. Hugh McTavish, is both a practicing patent attorney and a Ph.D. biochemist with extensive laboratory experience. He is a cancer survivor himself, and he knows first-hand how horrible chemotherapy can be. Now, he is dedicated to finding better and more effective anti-cancer drugs. IGF Oncology is a biotech company developing targeted anti-cancer drugs with better efficacy and lower side effects compared to existing chemotherapy treatments. Their lead drug, IGF-MTX, targets the deadly blood cancer MDS, and is currently in clinical trials at the Mayo Clinic. The results so far are very promising.